The University of Chicago Header Logo

Connection

Stephen Hanauer to Remission Induction

Back to Details
This is a "connection" page, showing publications Stephen Hanauer has written about Remission Induction.
Stephen Hanauer
Connection Strength
3.134
Remission Induction
  1. Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes. J Crohns Colitis. 2020 Oct 05; 14(10):1345-1353.
    View in: PubMed
    Score: 0.167
  2. Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis. J Crohns Colitis. 2020 Sep 16; 14(9):1274-1281.
    View in: PubMed
    Score: 0.166
  3. Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. Clin Gastroenterol Hepatol. 2019 07; 17(8):1525-1532.e1.
    View in: PubMed
    Score: 0.145
  4. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflamm Bowel Dis. 2016 08; 22(8):1870-80.
    View in: PubMed
    Score: 0.125
  5. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-a biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013 Dec; 145(6):1464-78.e1-5.
    View in: PubMed
    Score: 0.104
  6. Treat the patient or treat the disease? Dig Dis. 2012; 30(4):400-3.
    View in: PubMed
    Score: 0.094
  7. A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease. Gut. 2013 Sep; 62(9):1288-94.
    View in: PubMed
    Score: 0.094
  8. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2010 Dec 08; (12):CD008870.
    View in: PubMed
    Score: 0.084
  9. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther. 2010 Aug; 32(3):384-93.
    View in: PubMed
    Score: 0.081
  10. Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow? Gastroenterol Clin Biol. 2009 Jun; 33 Suppl 3:S202-8.
    View in: PubMed
    Score: 0.076
  11. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol. 2008 Jan 21; 14(3):354-77.
    View in: PubMed
    Score: 0.069
  12. Refining the role of TNF antagonists for Crohn's disease. Introduction. Rev Gastroenterol Disord. 2007; 7 Suppl 1:S1-2.
    View in: PubMed
    Score: 0.064
  13. A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology. 2007 Jan; 132(1):76-86.
    View in: PubMed
    Score: 0.064
  14. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment Pharmacol Ther. 2006 Oct; 24 Suppl 3:37-40.
    View in: PubMed
    Score: 0.063
  15. Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. J Clin Gastroenterol. 2006 Jul; 40(6):482-9.
    View in: PubMed
    Score: 0.062
  16. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005 Nov; 100(11):2478-85.
    View in: PubMed
    Score: 0.059
  17. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004 Sep; 127(3):723-9.
    View in: PubMed
    Score: 0.055
  18. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004 Jan; 99(1):91-6.
    View in: PubMed
    Score: 0.052
  19. Controversies with aminosalicylates in inflammatory bowel disease. Rev Gastroenterol Disord. 2004; 4(3):104-17.
    View in: PubMed
    Score: 0.052
  20. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies. Rev Gastroenterol Disord. 2004; 4 Suppl 3:S18-24.
    View in: PubMed
    Score: 0.052
  21. Neuroimmune Modulation Through Vagus Nerve Stimulation Reduces Inflammatory Activity in Crohn's Disease Patients: A Prospective Open-label Study. J Crohns Colitis. 2023 Dec 30; 17(12):1897-1909.
    View in: PubMed
    Score: 0.052
  22. Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2024 01; 22(1):144-153.e2.
    View in: PubMed
    Score: 0.050
  23. A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis. Aliment Pharmacol Ther. 2023 08; 58(3):283-296.
    View in: PubMed
    Score: 0.050
  24. Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol. 2003 Feb; 17(1):131-7.
    View in: PubMed
    Score: 0.049
  25. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022 06 11; 399(10342):2200-2211.
    View in: PubMed
    Score: 0.047
  26. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002 May 04; 359(9317):1541-9.
    View in: PubMed
    Score: 0.046
  27. Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results. Gastroenterology. 2022 06; 162(7):1876-1890.
    View in: PubMed
    Score: 0.046
  28. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. Lancet Gastroenterol Hepatol. 2022 01; 7(1):28-37.
    View in: PubMed
    Score: 0.045
  29. Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. J Crohns Colitis. 2021 Jul 05; 15(7):1120-1129.
    View in: PubMed
    Score: 0.044
  30. Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. Clin Gastroenterol Hepatol. 2022 03; 20(3):578-590.e4.
    View in: PubMed
    Score: 0.043
  31. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol. 2000 Jul; 95(7):1749-54.
    View in: PubMed
    Score: 0.041
  32. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000 May; 95(5):1263-76.
    View in: PubMed
    Score: 0.040
  33. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Aliment Pharmacol Ther. 2018 07; 48(1):65-77.
    View in: PubMed
    Score: 0.035
  34. Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. Inflamm Bowel Dis. 2018 05 18; 24(6):1291-1297.
    View in: PubMed
    Score: 0.035
  35. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016 11 17; 375(20):1946-1960.
    View in: PubMed
    Score: 0.032
  36. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. N Engl J Med. 2016 May 05; 374(18):1754-62.
    View in: PubMed
    Score: 0.031
  37. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015 Sep; 110(9):1324-38.
    View in: PubMed
    Score: 0.029
  38. Human Placenta-derived Cells (PDA-001) for the Treatment of Moderate-to-severe Crohn's Disease: A Phase 1b/2a Study. Inflamm Bowel Dis. 2015 Aug; 21(8):1809-16.
    View in: PubMed
    Score: 0.029
  39. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis. 2015 Jun; 21(6):1329-40.
    View in: PubMed
    Score: 0.029
  40. Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease. Inflamm Bowel Dis. 2014 Oct; 20(10):1722-8.
    View in: PubMed
    Score: 0.027
  41. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014 Sep; 147(3):618-627.e3.
    View in: PubMed
    Score: 0.027
  42. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis. 2014 Sep; 8(9):927-35.
    View in: PubMed
    Score: 0.027
  43. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014 Nov; 63(11):1721-7.
    View in: PubMed
    Score: 0.026
  44. Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease. Inflamm Bowel Dis. 2013 Nov; 19(12):2577-83.
    View in: PubMed
    Score: 0.026
  45. Safety and tolerability of human placenta-derived cells (PDA001) in treatment-resistant crohn's disease: a phase 1 study. Inflamm Bowel Dis. 2013 Mar-Apr; 19(4):754-60.
    View in: PubMed
    Score: 0.025
  46. Long-term treatment of patients with a history of ulcerative colitis who develop gastritis and pan-enteritis after colectomy. J Clin Gastroenterol. 2013 Jan; 47(1):52-7.
    View in: PubMed
    Score: 0.024
  47. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012 Oct 18; 367(16):1519-28.
    View in: PubMed
    Score: 0.024
  48. What changes in inflammatory bowel disease management can be implemented today? J Crohns Colitis. 2012 Feb; 6 Suppl 2:S260-7.
    View in: PubMed
    Score: 0.023
  49. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011 Oct; 141(4):1194-201.
    View in: PubMed
    Score: 0.022
  50. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2011 Aug; 34(3):306-17.
    View in: PubMed
    Score: 0.022
  51. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011 Apr; 106 Suppl 1:S2-25; quiz S26.
    View in: PubMed
    Score: 0.022
  52. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis. 2012 Jan; 18(1):10-6.
    View in: PubMed
    Score: 0.022
  53. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr; 106(4):644-59, quiz 660.
    View in: PubMed
    Score: 0.021
  54. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011 Jun; 60(6):780-7.
    View in: PubMed
    Score: 0.021
  55. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011 Feb; 106(2):199-212; quiz 213.
    View in: PubMed
    Score: 0.021
  56. Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study. BMC Gastroenterol. 2009 Mar 20; 9:22.
    View in: PubMed
    Score: 0.019
  57. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease. Am J Gastroenterol. 2008 Dec; 103(12):3123-31.
    View in: PubMed
    Score: 0.018
  58. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2007 Oct; 13(10):1250-5.
    View in: PubMed
    Score: 0.017
  59. Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease. J Pediatr Gastroenterol Nutr. 2007 Sep; 45(3):312-8.
    View in: PubMed
    Score: 0.017
  60. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007 Jul 19; 357(3):239-50.
    View in: PubMed
    Score: 0.017
  61. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007 Jun 19; 146(12):829-38.
    View in: PubMed
    Score: 0.016
  62. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007 Feb; 132(2):763-86.
    View in: PubMed
    Score: 0.016
  63. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007 Jan; 132(1):52-65.
    View in: PubMed
    Score: 0.016
  64. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 08; 353(23):2462-76.
    View in: PubMed
    Score: 0.015
  65. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005 Nov 03; 353(18):1912-25.
    View in: PubMed
    Score: 0.015
  66. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol. 2005 Aug; 100(8):1780-7.
    View in: PubMed
    Score: 0.015
  67. Maintaining remissions across the lifespan: a roundtable discussion with Crohn's disease experts. Inflamm Bowel Dis. 2004 Jul; 10 Suppl 2:S11-21.
    View in: PubMed
    Score: 0.013
  68. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology. 2000 Dec; 119(6):1461-72.
    View in: PubMed
    Score: 0.011
  69. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med. 2000 Jun 01; 342(22):1627-32.
    View in: PubMed
    Score: 0.010
  70. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology. 1999 Sep; 117(3):527-35.
    View in: PubMed
    Score: 0.010
  71. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997 Oct 09; 337(15):1029-35.
    View in: PubMed
    Score: 0.008
  72. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bone Marrow Transplant. 1996 Feb; 17(2):157-62.
    View in: PubMed
    Score: 0.008
  73. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci. 1995 Feb; 40(2):296-304.
    View in: PubMed
    Score: 0.007
  74. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology. 1993 May; 104(5):1293-301.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.